Skip to content
10-K

Annual Report

REGEN BIOPHARMA, INC. RGBP RGBPP

0001641172-25-009968

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Apr 30, 2025 21.55M sh
Shares Diluted FY 2024 · Sep 30, 2023 3.54M sh
Operating Cash Flow FY 2024 · Sep 30, 2023 −$173.92K
Cash And Equivalents FY 2024 · Sep 30, 2023 $121.04K
Current Liabilities restated FY 2024 · Sep 30, 2023 $5.31M
Total Liabilities restated FY 2024 · Sep 30, 2023 $5.46M
Current Assets FY 2024 · Sep 30, 2023 $131.04K
Total Assets FY 2024 · Sep 30, 2023 $353.62K
Eps Diluted FY 2024 · Sep 30, 2023 $0.29
Eps Basic FY 2024 · Sep 30, 2023 $0.29
Rd Expense FY 2024 · Sep 30, 2023 $212.3K
Net Income FY 2024 · Sep 30, 2023 $1.16M
Operating Income FY 2024 · Sep 30, 2023 −$686.95K
Revenue FY 2024 · Sep 30, 2023 $236.56K
Stockholders Equity FY 2024 · Sep 30, 2022 −$8.04M